Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R K Maitra

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|May 23, 1998
Nuclease-resistant composite 2',5'-oligoadenylate-3', 5'-oligonucleotides for the targeted destruction of RNA: 2-5A-iso-antisenseW Xiao, G Li, M R Player, et al.
International Journal of Surgery (London, England)|June 25, 2013
Should laparoscopic reversal of Hartmann's procedure be the first line approach in all patients?R K Maitra, T D Pinkney, M K Mohiuddin, et al.
Virology|November 1, 1994
HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymesR K Maitra, N A McMillan, S Desai, et al.
Science (New York, N.Y.)|August 5, 1994
Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimerasA Maran, R K Maitra, A Kumar, et al.
AIDS Research and Human Retroviruses|March 1, 1996
The nef gene from a long-term HIV type 1 nonprogressorD R Premkumar, X Z Ma, R K Maitra, et al.
Blood|December 3, 1998
2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cellsA Maran, C F Waller, J M Paranjape, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|May 23, 1998
Nuclease-resistant composite 2',5'-oligoadenylate-3', 5'-oligonucleotides for the targeted destruction of RNA: 2-5A-iso-antisenseW Xiao, G Li, M R Player, et al.
International Journal of Surgery (London, England)|June 25, 2013
Should laparoscopic reversal of Hartmann's procedure be the first line approach in all patients?R K Maitra, T D Pinkney, M K Mohiuddin, et al.
Virology|November 1, 1994
HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymesR K Maitra, N A McMillan, S Desai, et al.
Science (New York, N.Y.)|August 5, 1994
Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimerasA Maran, R K Maitra, A Kumar, et al.
AIDS Research and Human Retroviruses|March 1, 1996
The nef gene from a long-term HIV type 1 nonprogressorD R Premkumar, X Z Ma, R K Maitra, et al.
Blood|December 3, 1998
2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cellsA Maran, C F Waller, J M Paranjape, et al.
Pageof 2